PEDIATRICS · 2005 · 132 citations · 7 references
MedicineImmunologyPharmacotherapyImmunotherapyInflammationRheumatologyAnti-inflammatory PharmacologyInflammatory LesionsInflammatory PathologyOsteomyelitisOsteomyelitis ManagementChronic Recurrent OsteomyelitisOsteomyelitis RecurrenceSwellingTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
We describe the case of an 18-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) over a period of 10 years. She had suffered predominantly from very painful recurrent swelling of her cheeks. Various therapeutic regimens including nonsteroidal antiinflammatory drugs and steroids had shown only a partial or temporary response. Because tumor necrosis factor-alpha-blocking agents have been successfully applied in Crohn's-associated CRMO and the related SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, tumor necrosis factor-alpha-blocking therapy with infliximab was initiated. Thereafter, apart from 1 mild episode, no additional recurrences were observed during 21 months of follow-up. Infliximab was well tolerated, and steroids were tapered off. Our observation indicates that infliximab may be an effective therapeutic option in CRMO.
7
Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept
Mercedeh Baghai, Douglas R. Osmon, Donna M. Wolk et al. · Mayo Clinic Proceedings · 2001 · 133 citations
SAPHO: Rare or just not recognized?
Sharon Van Doornum, David Barraclough, Geoff McColl et al. · Seminars in Arthritis and Rheumatism · 2000 · 132 citations
Veterinary Medicine, Infectious Diseases, Zoonotic Diseases +2